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The immunological significance of IL-27 has been reported and discussed in various Th1/Th17-mediated
inflammatory diseases. However, its importance in psoriasis is unknown. We investigated pathophysiological
roles of IL-27 in psoriasis in this study. Serum IL-27 levels in psoriatic patients were significantly higher than
those in healthy controls, and correlated with disease severity and serum IFN-g levels. An immunohistochemical
analysis revealed the infiltration of IL-27-secreting cells in the papillary dermis of psoriatic skin lesions but not in
skin lesions with atopic dermatitis or normal skin. Furthermore, IL-27 alone greatly induced in vitro CXCL9,
CXCL10, and CXCL11 production and tyrosine phosphorylation of signal transducer and activator of
transcription 1 in normal human keratinocytes, while it suppressed the tumor necrosis factor-a-induced
production of IL-1a and CCL20. These results indicate that IL-27 may promote the onset of psoriasis, while it may
simultaneously attenuate the expanded inflammation in this disease. Our results implicate potential therapeutic
effects of IL-27 for psoriasis.
Journal of Investigative Dermatology (2010) 130, 1034–1039; doi:10.1038/jid.2009.349; published online 19 November 2009
INTRODUCTION
Psoriasis is a cutaneous disorder characterized by epidermal
hyperproliferation and inflammation with a marked infiltra-
tion of T cells, neutrophils, and macrophages. Psoriatic
inflammation was once considered to be mediated by T
helper 1 (Th1) cells, however, recent studies increasingly
indicate that immune responses by newly characterized Th17
cells are also involved in the pathogenesis of psoriasis (Fitch
et al., 2007; Lowes et al., 2007, 2008; Wilson et al., 2007).
IL-27, a member of IL-12 family, is a recently discovered
cytokine, consisting of p28 and Epstein–Barr virus-induced
gene protein 3 subunits, and is mainly produced by activated
antigen-presenting cells (Batten and Ghilardi, 2007). IL-27 is
involved in the priming of Th1 cells. Initial reports described
that IL-27 promoted Th1 differentiation from naive T cells
through signal transducer and activator of transcription 1
(STAT1)-dependent pathways, inducing the production of
IFN-g (Takeda et al., 2003; Owaki et al., 2005). However,
subsequent studies have reported diverse functions of IL-27.
IL-27 suppresses Th17 and Th2 differentiation and inhibits the
production of proinflammatory cytokines, such as tumor
necrosis factor-a (TNF-a) and IL-12p40 in macrophages, or
IL-2, IL-6, and IL-17 in Th cells (Yoshimura et al., 2006;
Kastelein et al., 2007; Diveu et al., 2008; Stumhofer and
Hunter, 2008).
The pathophysiological significance of IL-27 has been
reported and discussed in Th1/Th17-mediated inflammatory
diseases, such as rheumatoid arthritis, multiple sclerosis, and
inflammatory bowel diseases (Honda et al., 2005; Schmidt
et al., 2005; Batten, 2006; Fitzgerald et al., 2007; Cao et al.,
2008; Niedbala et al., 2008). However, the roles of IL-27 in
psoriasis are unknown. The purpose of this study was to
investigate the significance of IL-27 in the pathogenesis of
psoriasis.
RESULTS
Serum IL-27 level in psoriatic patients and its correlation with
the disease severity
The serum IL-27 levels in psoriatic patients were significantly
higher than those in healthy controls (452±254 vs 318±
239pgml1, Po0.005) (Figure 1a). We next estimated the
correlation between serum IL-27 levels and psoriasis area and
severity index (PASI) scores, reflecting the severity of psoriasis. As
shown in Figure 1b, a significant correlation was found
(r¼ 0.629, Po0.005) between these factors in psoriatic patients.
Correlation of serum IL-27 and IFN-c levels in psoriatic patients
IL-27 is reported to enhance IFN-g production in T cells and
suppresses the production of TNF-a and IL-12p40 in
macrophages, or of IL-17 in T cells. Thus, we next measured
serum levels of these cytokines and studied the correlations of
them with IL-27 level in psoriatic patients. Serum IL-12p40
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levels in psoriasis patients were significantly higher than
those in healthy controls (121±12 vs 88±10 pgml1,
Po0.05). Serum levels of IFN-g and IL-17 did not vary
between these two groups (data not shown). A significant
correlation was found (r¼0.415, Po0.05) between serum
IL-27 and IFN-g levels (Figure 1c), although there were no
significant correlations between serum IL-27 levels and those
of TNF-a, IL-12p40, or IL-17 levels (data not shown). As to the
correlations of these factors with PASI scores, we found a
significant correlation (r¼0.368, Po0.05) only between
PASI scores and serum IL-12p40 levels.
Infiltration of IL-27-secreting cells in the skin lesions with
psoriasis
To investigate the distribution of IL-27-secreting cells, we
performed immunohistochemical staining. IL-27-positive
cells were found among the infiltrating cells of the papillary
dermis in psoriatic skin lesions. However, there were no
IL-27-positive cells in skin lesions with atopic dermatitis or
normal skin (Figure 2).
IL-27 upregulated the production of CXCL9, CXCL10, and
CXCL11 in normal human keratinocytes
Next, we evaluated the in vitro effects of IL-27 on the
production of cytokines and chemokines in normal human
keratinocytes. It is reported that these cells express IL-27
receptor subunits, gp130 and WSX-1 (Kanda and Watanabe,
2008). IL-27 greatly induced the production of CXCL9,
CXCL10, and CXCL11 in keratinocytes (Figure 3a). Because
these chemokines are known to be induced by the activation
of STAT1 (Kanda and Watanabe, 2007), we examined
whether IL-27 induces the activation of STAT1 by analyzing
the tyrosine phosphorylation of STAT1 in keratinocytes. IL-27
induced the tyrosine phosphorylation of STAT1 from 10 until
60 minutes after the stimulation (Figure 3b).
IL-27 suppressed the TNF-a-induced production of IL-1a and
CCL20 in normal human keratinocytes
IL-27, administered alone, had no effects on the production
of CCL20, IL-1a, IL-1b, IL-6, IL-8, IL-10, IL-12p40, IL-23,
IL-20, and IL-22 in normal human kerationcytes (data not
shown). When keratinocytes were stimulated with TNF-a, the
production of IL-6, IL-8, IL-1a, and CCL20 was enhanced.
IL-27 dose dependently suppressed the TNF-a-induced
production of IL-1a and CCL20 (Figure 4) but not that of
IL-6 and IL-8 (data not shown).
DISCUSSION
This study showed the elevated serum IL-27 levels in psoriatic
patients and the multiple immunological effects of IL-27 on
normal human keratinocytes. To our knowledge, the involve-
ment of IL-27 in the pathogenesis of psoriasis is previously
unreported.
IL-27 is a rather complex cytokine; it promotes Th1
differentiation and enhances the activities of Th1, whereas it
exerts immunosuppressive and anti-inflammatory effects on
Th17 cells (Yoshimura et al., 2006; Batten and Ghilardi,
2007; Kastelein et al., 2007; Diveu et al., 2008; Stumhofer
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Figure 1. Serum IL-27 levels in psoriatic patients and healthy controls (a)
and their correlation with PASI scores (b) or serum IFN-g levels (c) in
psoriatic patients. (a) Serum IL-27 levels in psoriatic patients were
significantly higher than those in healthy controls (Po0.005, by
Mann–Whitney U-test). The horizontal and error bars indicate mean±SD.
(b) A significant positive correlation was found between serum
IL-27 levels and PASI scores in psoriatic patients (r¼ 0.629, Po0.005, by
Spearman’s rank correlation test). The solid line represents the regression line.
(c) A significant positive correlation was found between serum IL-27 and
IFN-g levels (r¼0.415, Po0.05, by Spearman’s rank correlation test).
The solid line represents the regression line.
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and Hunter, 2008). It is thus important to investigate the roles
of IL-27 in the diseases that were once considered as Th1 type
and are now increasingly recognized as Th17 type, such as
psoriasis, rheumatoid arthritis, multiple sclerosis, and inflam-
matory bowel diseases.
In our study, serum IL-27 levels in psoriatic patients were
elevated compared with those of healthy controls, and
furthermore, significantly correlated with disease severity.
Serum IL-27 levels also positively correlated with those of
IFN-g in psoriatic patients, indicating that the increased IL-27
levels may contribute to the enhanced Th1 activity in
psoriatic patients. IL-27 derived from antigen-presenting cells
induces their IFN-g production in T cells (Pflanz et al., 2002;
Takeda et al., 2003; Owaki et al., 2005), whereas IFN-g in
turn exerts its effect on antigen-presenting cells and
upregulates their production of IL-27 (Liu et al., 2007; Molle
et al., 2007). Thus, the positive correlation between serum IL-
27 and IFN-g levels in this study indicates a possible self-
sustaining inflammatory loop of IL-27/IFN-g. Conversely, the
positive correlation between serum IL-27 levels and disease
severity also suggests that the increase of IL-27 may be a
compensatory mechanism to downregulate the enhanced
Th17 activity in psoriatic patients. However, serum IL-17
levels showed neither positive nor negative correlation with
those of IL-27 at least in our patient population. One possible
reason for the rather discrepant results is that IL-27 can only
partially counteract the Th17 activities in psoriatic patients.
Consistent with our results, the enhanced expression of IL-27
and its correlation with disease severity have been reported in
various so-called Th1/Th17 inflammatory diseases (Honda
et al., 2005; Schmidt et al., 2005; Batten, 2006; Fitzgerald
et al., 2007; Cao et al., 2008; Niedbala et al., 2008).
However, studies using animal models of Th1/Th17 diseases
reported variable results; some showed exacerbation of the
diseases by IL-27, whereas others reported their improvement
by IL-27. It still remains controversial whether the increase of
IL-27 indicates its proinflammatory role to activate Th1 cells
or is a sign of a regulatory mechanism to limit Th17 cell
activity (Li et al., 2005; Schmidt et al., 2005; Fitzgerald et al.,
2007; Niedbala et al., 2008; Shahrara et al., 2008).
The immunohistochemical study revealed the infiltration
of IL-27-secreting cells, possibly dendritic cells, in psoriatic
skin lesions, but not in normal skin or lesions with atopic
dermatitis, another chronic inflammatory dermatosis. The
results indicate that IL-27 may specifically act in psoriatic
lesions. We also examined the effects of IL-27 on keratino-
cytes. IL-27 by itself induced a strong production of CXCL9,
CXCL10, and CXCL11 and tyrosine phosphorylation of
STAT1 in keratinocytes. The tyrosine phosphorylation
of STAT1 induces its dimerization, nuclear translocation,
and DNA binding, and the production of CXCL9, CXCL10,
and CXCL11 is dependent on STAT1 activities (Kanda and
Watanabe, 2007). These chemokines selectively attract
activated Th1 cells through the cell-surface CXC chemokine
Figure 2. Immunohistochemical analyses of skin lesions with psoriasis (a, d, g), atopic dermatitis (b, e, h) and of normal skin from a healthy volunteer
(c, f, i). Bar¼ 100mm. The left panels (a–c) show IL-27 staining of intermediate-power view (original magnification, 80), the middle panels (d–f) show IL-27
staining of high-power view (original magnification,  160), and the right panels (g–i) show staining with isotype-matched control IgG of intermediate-
power view (original magnification,  80). The arrows indicate IL-27-positive cells in psoriatic skin lesions. Representative staining of each group is shown.
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receptor 3. The expression of these chemokines is upregu-
lated in the keratinocytes of psoriatic skin lesions (Gottlieb
et al., 1988; Flier et al., 2001; Giustizieri et al., 2001).
Besides, CXC chemokine receptor 3 is selectively expressed
on skin-homing cutaneous lymphocyte antigen-positive
lymphocytes in psoriatic skin lesions (Rottman et al., 2001).
Taken together with our results, IL-27 might promote Th1-
type inflammation by activating STAT1 in the absence of
other inflammatory mediators in psoriatic patients and
contribute to the onset of the disease.
In contrast, IL-27 exerted anti-inflammatory effects on
keratinocytes in the presence of TNF-a. Although IL-27 by
itself had no effects on the production of IL-1a and CCL20, it
inhibited the TNF-a-induced production of these factors.
TNF-a is a key cytokine for the exacerbation of psoriasis, as
the blockade of TNF-a by etanercept effectively reduced
Th17 responses in psoriasis (Zaba et al., 2007). IL-1 is also an
important cytokine that induces the production of various
secondary cytokines and chemokines in keratinocytes (Bau-
mann and Gauldie, 1994). CCL20 selectively attracts Th17
cells through the cell-surface CC chemokine receptor 6 and is
thus a key chemokine for the acceleration of psoriasis
(Homey et al., 2000; Holtmann et al., 2001; Harper et al.,
2007; Pene et al., 2008). Our results thus indicate that IL-27
may prevent the recruitment of Th17 cells into psoriatic
lesions through downregulation of CCL20. Though CCL20
and IL-1a still exist after treatment with IL-27 (Figure 4), IL-27
may at least partially regulate the aberrant effects of TNF-a in
psoriatic lesions.
The results of this study indicate the possibility that IL-27
alone could prime the onset of psoriasis by inducing Th1-
attracting chemokines, but also it may suppress the expanded
inflammation of psoriasis when the disease has been
established and the expression of TNF-a is constantly
upregulated. Previous studies revealed that IL-27 suppresses
the development of Th17 cells and has anti-inflammatory
roles in Th cells (Yoshimura et al., 2006; Kastelein et al.,
2007; Diveu et al., 2008; Stumhofer and Hunter, 2008).
Taken together, topical application of IL-27 could be
therapeutically beneficial to established psoriatic skin le-
sions, by exerting anti-inflammatory effects both on kerati-
nocytes and Th cells.
In summary, we showed the involvement of IL-27 in the
pathogenesis of psoriasis and suggested possible mechanisms
by which manipulation of IL-27 may be of therapeutic
significance in psoriasis.
MATERIALS AND METHODS
All the experiments were conducted in accordance with the
Declaration of Helsinki Principles.
Patients and measurement of serum cytokine levels
A total of 42 patients with psoriasis vulgaris (33 men and 9
women; aged 51.8±11.9 years) and 39 healthy controls (32 men
and 7 women; aged 49.8±9.4 years) from the Faculty of
Medicine, Department of Dermatology, University of Tokyo
were enrolled in the study. All the psoriatic patients were treated
with topical steroids and/or topical vitamin D3. The disease
activity of psoriasis was assessed by PASI scores (Fredriksson and
Pettersson, 1978). Patients and healthy volunteers gave us written
informed consent to participate in this study, which has been
approved by the medical ethical committee of the University of
Tokyo. Serum samples were stored at 20 1C and serum levels of
cytokines and chemokines were measured using ELISA (R&D
Systems, Minneapolis, MN) according to the manufacturer’s
directions.
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Figure 3. Effects of IL-27 on the production of CXCL9, CXCL10, and CXCL11
and tyrosine phosphorylation of signal transducer and activator of
transcription-1 (STAT1) in keratinocytes. (a) Data are mean±SD (n¼ 4) and
are representative of three independent experiments. *Po0.05 versus
controls, by Mann–Whitney U-test. (b) Results are representative of four
independent experiments.
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Immunohistochemical staining
Biopsies were taken from skin lesions of five psoriatic patients, five
patients with atopic dermatitis, and from normal skin of two healthy
volunteers after obtaining informed consent. The samples were
formalin fixed and embedded in paraffin. The tissue sections (5 mm)
were deparaffinized, rehydrated, and blocked with hydrogen
peroxide. After boiling for 10minutes for antigen retrieval, the slides
were incubated overnight at 4 1C with the goat IgG anti-mouse
IL-27p28 polyclonal antibody (R&D Systems) or non-immune goat
IgG (Vector Laboratories, Burlingame, CA) at the concentration of
5mgml1. The samples were washed with phosphate-buffered saline
and incubated with biotin-conjugated rabbit anti-goat IgG supplied
by ABC staining kit (Vector Laboratories) for 2 hours at room
temperature. After an additional washing step, the samples were
incubated with the Vecstatin ABC-AP reagent followed by alkaline-
phosphatase substrate solution, and counterstained with Mayer
hematoxylin.
Reagents
Recombinant human IL-27 and TNF-a were obtained from R&D
Systems.
Cell culture
Normal human epidermal keratinocytes were cultured with
MCDB153 medium supplemented with insulin (5 mgml1),
hydrocortisone (1mM), ethanolamine (0.1mM), phosphoethanola-
mine (0.1mM), bovine hypothalamic extract (50 mgml1), and Ca2þ
(0.1mM) as described previously (Shirakata et al., 2000, 2003).
Cytokine or chemokine secretion from keratinocytes
Normal human epidermal keratinocytes were seeded on 12-well
plates at a density of 5 104 cells per well. After reaching
subconfluency, the cells were fed with MCDB153 medium lacking
bovine hypothalamic extract. The following day, the cells were fed
once again with the same medium containing IL-27 and/or TNF-a at
the indicated concentrations and incubated for 48 hours. The levels
of cytokines and chemokines in the supernatants were measured
using ELISA kits from R&D Systems according to the manufacturer’s
directions.
Western blot analysis
Subconfluent kerationocytes were lysed in lysis buffer (20mM Tris
(pH 7.5), 150mM NaCl, 1mM EDTA, 1mM EGTA, 1% Triton X-100,
2.5mM sodium pyrophosphate, 1mM glycerophosphate, 1mM
sodium orthovanadate, 1mM phenylmethylsulfonyl fluoride, and
1mgml1 leupeptin). Samples were dissolved in NuPAGE LDS
Sample Buffer with NuPAGE Sample Reducing Agent (Invitrogen,
Carlsbad, CA) and denatured by heating 5minutes at 95 1C.
SDS–PAGE was performed with NuPAGE 4–12% Bis-Tris gels and
MES running buffer (Invitrogen). After transfer to an Immobilon-P
transfer membrane (Millipore, Bedford, MA), the membrane was
blotted with the primary antibody overnight at 4 1C and with the
appropriate secondary antibody for 1 hour at room temperature.
Visualization was performed by enhanced chemiluminescence
(Amersham Pharmacia Biotech, Buckinghamshire, UK).
Statistical analyses
Data obtained are presented as mean±SD. Comparisons were
performed using the Mann–Whitney U-test and correlation coeffi-
cients were determined by using the Spearman’s rank correlation
test. P-values o0.05 were considered to represent a significant
difference. All statistical analyses were performed using the SPSS
11.0 system (SPSS Inc., Chicago, IL).
CONFLICT OF INTEREST
The authors state no conflict of interest.
ACKNOWLEDGMENTS
This work was supported by grants from the Ministry of Education, Culture, Sports,
Science, and Technology of Japan (17209039 to K.T. and 20591336 to Y.T.).
REFERENCES
Batten M, Li J, Yi S et al. (2006) Interleukin-27 limits autoimmune
encephalomyelitis by suppressing the development of interleukin 17
producing T cells. Nat Immunol 7:929–36
Batten M, Ghilardi N (2007) The biology and therapeutic potential of
interleukin 27. J Mol Med 85:661–72
Baumann H, Gauldie J (1994) The acute phase response. Immunol Today
15:74–80
Cao Y, Doodes PD, Glant TT et al. (2008) IL-27 induces a Th1 immune
response and susceptibility to experimental arthritis. J Immunol
180:922–30
10
9
8
7
6
5
4
3
2
1
0
IL
-1
α
 
(ng
/m
l)
600
500
400
300
200
100
0
0 100 0 1 10 100
TNFα 10 ng/ml
IL-27 (ng/ml)
IL-27 (ng/ml)
CC
L2
0 
(ng
/m
l)
*
**
**
**
**
*
0 100 0 1 10 100
TNFα 10 ng/ml
Figure 4. Effects of IL-27 on the TNF-a-induced production of IL-1a and
CCL20 in keratinocytes. Data are mean±SD (n¼6) and are representative of
five independent experiments. *Po0.05 versus controls with medium alone;
**Po0.05 versus TNF-a alone, by Mann–Whitney U-test.
1038 Journal of Investigative Dermatology (2010), Volume 130
S Shibata et al.
IL-27 and Psoriasis
Diveu C, McGeachy MJ, Cua DJ (2008) Cytokines that regulate autoimmunity.
Curr Opin Immunol 20:663–8
Fitch E, Harper E, Skorcheva I et al. (2007) Pathophysiology of psoriasis:
recent advances on IL-23 and Th17 cytokines. Curr Rheumatol Rep
9:461–7
Fitzgerald DC, Ciric B, Touil T et al. (2007) Suppressive effect of IL-27 on
encephalitogenic Th17 cells and the effector phase of experimental
autoimmune encephalomyelitis. J Immunol 179:3268–75
Flier J, Boorsma DM, van Beek PJ et al. (2001) Differential expression of
CXCR3 targeting chemokines CXCL10, CXCL9, and CXCL11 in different
types of skin inflammation. J Pathol 194:398–405
Fredriksson T, Pettersson U (1978) Severe psoriasis—oral therapy with a new
retinoid. Dermatologica 157:238–44
Giustizieri ML, Mascia F, Frezzolini A et al. (2001) Keratinocytes from
patients with atopic dermatitis and psoriasis show a distinct chemokine
production profile in response to T cell-derived cytokines. J Allergy Clin
Immun 107:871–7
Gottlieb AB, Luster AD, Posnett DN et al. (1988) Detection of a gamma
interferon-induced protein IP-10 in psoriatic plaques. J Exp Med 168:941–8
Harper EG, Guo C, Rizzo H et al. (2009) Th17 cytokines stimulate CCL20
expression in keratinocytes in vitro and in vivo: implications for psoriasis
pathogenesis. J Invest Dermatol 129:2175–83
Holtmann H, Enninga J, Kalble S et al. (2001) The MAPK kinase kinase TAK1
plays a central role in coupling the interleukin-1 receptor to both
transcriptional and RNA-targeted mechanisms of gene regulation. J Biol
Chem 276:3508–16
Homey B, Dieu-Nosjean MC, Wiesenborn A et al. (2000) Up-regulation of
macrophage inflammatory protein-3 alpha/CCL20 and CC chemokine
receptor 6 in psoriasis. J Immunol 164:6621–32
Honda K, Nakamura K, Matsui N et al. (2005) T helper 1-inducing property of
IL-27/WSX-1 signaling is required for the induction of experimental
colitis. Inflamm Bowel Dis 11:1044–52
Kanda N, Watanabe S (2007) Prolactin enhances interferon-gamma-induced
production of CXC ligand 9 (CXCL9), CXCL10, and CXCL11 in human
keratinocytes. Endocrinology 148:2317–25
Kanda N, Watanabe S (2008) IL-12, IL-23, and IL-27 enhance human beta-
defensin-2 production in human keratinocytes. Eur J Immunol
38:1287–96
Kastelein RA, Hunter CA, Cua DJ (2007) Discovery and biology of IL-23 and
IL-27: related but functionally distinct regulators of inflammation. Annu
Rev Immunol 25:221–42
Li J, Gran B, Zhang GX et al. (2005) IL-27 subunits and its receptor (WSX-1)
mRNAs are markedly up-regulated in inflammatory cells in the CNS during
experimental autoimmune encephalomyelitis. J Neurol Sci 232:3–9
Liu J, Guan X, Ma X (2007) Regulation of IL-27 p28 gene expression in
macrophages through MyD88- and interferon-gamma-mediated path-
ways. J Exp Med 204:141–52
Lowes MA, Bowcock AM, Krueger JG (2007) Pathogenesis and therapy of
psoriasis. Nature 445:866–73
Lowes MA, Kikuchi T, Fuentes-Duculan J et al. (2008) Psoriasis vulgaris
lesions contain discrete populations of Th1 and Th17 T cells. J Invest
Dermatol 128:1207–11
Molle C, Nguyen M, Flamand V et al. (2007) IL-27 synthesis induced by TLR
ligation critically depends on IFN regulatory factor 3. J Immunol
178:7607–15
Niedbala W, Cai B, Wei X et al. (2008) Interleukin 27 attenuates collagen-
induced arthritis. Ann Rheum Dis 67:1474–9
Owaki T, Asakawa M, Morishima N et al. (2005) A role for IL-27 in early
regulation of Th1 differentiation. J Immunol 175:2191–200
Pene J, Chevalier S, Preisser L et al. (2008) Chronically inflamed human
tissues are infiltrated by highly differentiated Th17 lymphocytes.
J Immunol 180:7423–30
Pflanz S, Timans JC, Cheung J et al. (2002) IL-27, a heterodimeric cytokine
composed of EBI3 and p28 protein, induces proliferation of naive
CD4(+) T cells. Immunity 16:779–90
Rottman JB, Smith TL, Ganley KG et al. (2001) Potential role of the chemokine
receptors CXCR3, CCR4, and the integrin alphaEbeta7 in the pathogen-
esis of psoriasis vulgaris. Lab Invest 81:335–47
Schmidt C, Giese T, Ludwig B et al. (2005) Expression of interleukin-12-
related cytokine transcripts in inflammatory bowel disease: elevated
interleukin-23p19 and interleukin-27p28 in Crohn’s disease but not in
ulcerative colitis. Inflamm Bowel Dis 11:16–23
Shahrara S, Huang Q, Mandelin AM II et al. (2008) TH-17 cells in rheumatoid
arthritis. Arthritis Res Ther 10:R93
Shirakata Y, Komurasaki T, Toyoda H et al. (2000) Epiregulin, a novel
member of the epidermal growth factor family, is an autocrine
growth factor in normal human keratinocytes. J Biol Chem 275:
5748–53
Shirakata Y, Tokumaru S, Yamasaki K et al. (2003) So-called biological
dressing effects of cultured epidermal sheets are mediated by the
production of EGF family, TGF-beta and VEGF. J Dermatol Sci
32:209–15
Stumhofer JS, Hunter CA (2008) Advances in understanding the anti-
inflammatory properties of IL-27. Immunol Lett 117:123–30
Takeda A, Hamano S, Yamanaka A et al. (2003) Cutting edge: role of IL-27/
WSX-1 signaling for induction of T-bet through activation of STAT1
during initial Th1 commitment. J Immunol 170:4886–90
Wilson NJ, Boniface K, Chan JR et al. (2007) Development, cytokine profile
and function of human interleukin 17-producing helper T cells. Nat
Immunol 8:950–7
Yoshimura T, Takeda A, Hamano S et al. (2006) Two-sided roles of IL-27:
induction of Th1 differentiation on naive CD4+ T cells versus
suppression of proinflammatory cytokine production including IL-23-
induced IL-17 on activated CD4+ T cells partially through STAT3-
dependent mechanism. J Immunol 177:5377–85
Zaba LC, Cardinale I, Gilleaudeau P et al. (2007) Amelioration of epidermal
hyperplasia by TNF inhibition is associated with reduced Th17
responses. J Exp Med 204:3183–94
www.jidonline.org 1039
S Shibata et al.
IL-27 and Psoriasis
